Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan 4;187(1):14-16.
doi: 10.1016/j.cell.2023.11.042.

Proteomics: A new dimension to decode small cell lung cancer

Haobin Chen  1 , Benjamin J Drapkin  2 , John D Minna  3
Affiliations
Comment

Proteomics: A new dimension to decode small cell lung cancer

Haobin Chen et al. Cell. .

Abstract

Small cell lung cancer (SCLC) is a recalcitrant malignancy. Conquering it will require deep insight into its biology. In this issue of Cell, Liu and colleagues describe proteomic and phosphoproteomic landscapes of resected SCLC tumors and illustrate the potential of this knowledge to identify new SCLC vulnerabilities.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests B.J.D. has consulting agreements with Astra Zeneca, Sonata Therapeutics, and Dialectic Therapeutics. J.D.M. receives royalties from the NIH and UTSW for distribution of human tumor cell lines.

Figures

Figure 1.
Figure 1.. The potential roles of proteomics in clinical translational research in small cell lung cancer (SCLC)
Proteomics, an integral component of multi-omics, should be applied to patients’ tumor samples; “preclinical” models, including patient-derived xenografts (PDXs), circulating tumor-cell-derived xenografts (CDXs), and genetically engineered mouse models (GEMMs); and in vitro SCLC cell lines. The insights gained from one model system inform other systems and promote innovations in multiple aspects of patient care, which might ultimately lead to conquering SCLC.
See this image and copyright information in PMC

Comment on

References

    1. Petty WJ, and Paz-Ares L (2023). Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review. JAMA Oncol. 9, 419–429. 10.1001/jamaoncol.2022.5631. - DOI - PubMed
    1. Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, et al. (2023). Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J. Clin. Oncol 41, 1200–1212. 10.1200/JCO.22.01503. - DOI - PMC - PubMed
    1. Qu S, Fetsch P, Thomas A, Pommier Y, Schrump DS, Miettinen MM, and Chen H (2022). Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. J. Thorac. Oncol 17, 141–153. 10.1016/j.jtho.2021.08.763. - DOI - PMC - PubMed
    1. Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, et al. (2020). New Approaches to SCLC Therapy: From the Laboratory to the Clinic. J. Thorac. Oncol 15, 520–540. 10.1016/j.jtho.2020.01.016. - DOI - PMC - PubMed
    1. Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, Phat S, Myers DT, Zhong J, Igo P, et al. (2018). Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discov. 8, 600–615. 10.1158/2159-8290.CD-17-0935. - DOI - PMC - PubMed

LinkOut - more resources